Mechanically, METTL3 inhibition triggers viral defense, interferon response and major histocompatibility complex (MHC)‐I expression, thereby inflaming immunologically cold tumours; and METTL3 inhibition sustains T‐cell persistence, simultaneously affecting both tumour cells and T cells to sensitise ICB‐based immunotherapy. Here, METTL3 is linked to neoplasm.